AML patients receive cancer drug DCP-001
December 3, 2018DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
More news
UvA spin-off Eddytec receives financing from Innovation Fund North Holland
Eddytec is developing an advanced hardware and software solution to make maintenance and quality control of carbon fiber composite parts in aircraft faster, easier and more affordable.
News
New prototype of Flowsure gets innovation into the clinic
How does valorisation work in a clinical setting? And how do you get an innovative idea to a patient’s bed?
News
UvA spin-off Hydra Computing is pioneering Classical-Quantum hybrid algorithms for Enhanced Combinatorial Optimization
Dr. Jiri Minar, dr. Juraj Hasik and dr. Arghavan Safavi-Naini obtained a Proof-of-Concept grant (100k EUR) from IXA-UvA to integrate state-of-the-art quantum physics inspired classical computational methods with quantum algorithms, to address the limitations of current quantum hardware, offering a groundbreaking solution for industries grappling with large datasets and complex optimization tasks. The primary goal […]
News